Rhythm Pharmaceuticals (RYTM) Equity Ratio (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Equity Ratio data on file, last reported at 0.28 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.28, up 467.1% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.28 (up 467.1% YoY), and the FY2025 annual result was 0.29, up 422.83% from the prior year.
• Equity Ratio fell to 0.28 in Q1 2026 per RYTM's latest filing, from 0.29 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.83 in Q1 2022 and troughed at 0.03 in Q2 2025.
• A 5-year average of 0.38 and a median of 0.29 in 2025 frame the typical range for Equity Ratio.
• On a YoY basis, Equity Ratio climbed as much as 851.8% in 2025 and fell as far as 131.01% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.69 in 2022, then retreated by 26.16% to 0.51 in 2023, then plunged by 89.14% to 0.06 in 2024, then surged by 422.83% to 0.29 in 2025, then declined by 4.05% to 0.28 in 2026.
• Business Quant data shows RYTM's Equity Ratio at 0.28 in Q1 2026, 0.29 in Q4 2025, and 0.29 in Q3 2025.